KRAS mutation (any)

Activating KRAS mutations (codons 12, 13, 61 and others) detected by sequencing or PCR; used as a predictive marker, including as a negative predictor of response to anti-EGFR antibodies in colorectal cancer.

CI-BIO-00000016KRAS graph →NCIt C41361 Tumor-agnostic · 4 approval rows

Also calledKRAS-mutant · KRAS-mutated · RAS mutation

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	95	89	6	—	4 / 35 / 25 / 31 / 0
Lung Non-Small Cell Carcinoma	31	25	5	1	2 / 24 / 1 / 3 / 1
Multiple Myeloma	17	13	4

Derived

Drugs with predictive evidence (57)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	47	6	41	A	5 / 39	Malignant Colorectal Neoplasm, Malignant Ovarian Neoplasm
PanitumumabMonoclonal Antibody	21	1	20	A	1 / 19	Colon Mucinous Adenocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	19	18	1	A	14 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
MelphalanSmall Molecule	13	—	13	B	0 / 13	Multiple Myeloma
ErlotinibSmall Molecule	11	3	8	B	1 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm +1
Chemotherapy	10	—	10	B	0 / 9	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	9	—	9	B	0 / 9	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Lung Neoplasm
Regorafenib AnhydrousSmall Molecule	9	1	8	B	0 / 7	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	8	7	1	A	5 / 1	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma
TrametinibSmall Molecule	8	7	1	B	5 / 1	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Pancreatic Adenocarcinoma
DactolisibSmall Molecule	7	7	—	D	7 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	5	1	4	B	0 / 4	Hairy Cell Leukemia, Malignant Colorectal Neoplasm, Melanoma
AfatinibSmall Molecule	4	4	—	C	4 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Ductal Adenocarcinoma
IrinotecanSmall Molecule	4	1	3	B	1 / 2	Malignant Colorectal Neoplasm
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	3	2	1	B	2 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm
AbemaciclibSmall Molecule	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm, Malignant Ovarian Serous Tumor
B-Raf/VEGFR-2 Inhibitor RAF265	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
CarboplatinSmall Molecule	2	1	1	B	1 / 1	Cutaneous Melanoma, Ovarian Carcinoma
DabrafenibSmall Molecule	2	—	2	B	0 / 2	Lung Adenocarcinoma, Melanoma
GemcitabineSmall Molecule	2	—	2	B	0 / 2	Malignant Pancreatic Neoplasm, Pancreatic Adenocarcinoma
PalbociclibSmall Molecule	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	2	2	—	B	2 / 0	Cutaneous Melanoma, Hepatocellular Carcinoma
SotorasibSmall Molecule	2	2	—	A	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
TeprotumumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	—	2	B	0 / 1	Malignant Colorectal Neoplasm
CrizotinibSmall Molecule	2	1	1	C	1 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm
RefametinibSmall Molecule	2	2	—	B	1 / 0	Hepatocellular Carcinoma, Malignant Colorectal Neoplasm
MEK Inhibitor RO4987655	2	1	1	B	—	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
Akt Inhibitor MK2206	1	1	—	C	1 / 0	Pancreatic Carcinoma
ARS-853	1	1	—	D	1 / 0	Malignant Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
AZD5438	1	1	—	D	1 / 0	Malignant Neoplasm
Cetuximab/Irinotecan Regimen	1	—	1	C	0 / 1	Malignant Colorectal Neoplasm
CisplatinSmall Molecule	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
DasatinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DecitabineSmall Molecule	1	1	—	D	1 / 0	Malignant Ovarian Neoplasm
DivarasibSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
G-573	1	1	—	D	1 / 0	Malignant Neoplasm
Immune Checkpoint Inhibitor	1	1	—	E	1 / 0	Lung Non-Small Cell Carcinoma
Immunomodulatory Oligonucleotide	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
IxazomibSmall Molecule	1	—	1	D	0 / 1	Malignant Colorectal Neoplasm
MEK Inhibitor GDC-0623	1	1	—	D	1 / 0	Malignant Neoplasm
NivolumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PaclitaxelSmall Molecule	1	—	1	B	0 / 1	Ovarian Carcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PI3Kbeta Inhibitor AZD8186	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
PictilisibSmall Molecule	1	—	1	D	0 / 1	Malignant Breast Neoplasm
SCH772984Small Molecule	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
SirolimusSmall Molecule	1	1	—	D	1 / 0	Lung Adenocarcinoma
Therapeutic Tumor Infiltrating Lymphocytes	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
RidaforolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm
SalirasibSmall Molecule	1	1	—	B	—	Lung Adenocarcinoma
TemsirolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (167)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 167 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS Q22*1
Panitumumab	Colon Mucinous Adenocarcinoma	Predictive	C	Supports Resistance	2	accepted	EID1131 A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC) PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC	civic
KRAS Amplification1
Carboplatin + Docetaxel + SorafenibCombination	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1497 Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved… (full text at CIViC) PMID 26307133 · Wilson et al., 2016 · Open in CIViC	civic
KRAS G12D4
Vemurafenib	Hairy Cell Leukemia	Predictive	C	Supports Resistance	2	accepted	EID1580 One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the… (full text at CIViC) PMID 26352686 · Tiacci et al., 2015 · Open in CIViC	civic
Dabrafenib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	2	accepted	EID91 A 63 year old patient was diagnosed with lung adenocarcinoma and received several treatment regimens over approximately three years, including carboplatin/paclitaxel, erlotinib, pemetrexed/bevacizumab… (full text at CIViC) PMID 23524406 · Rudin et al., 2013 · Open in CIViC	civic
Dactolisib + SelumetinibCombination	Lung Adenocarcinoma	Predictive	D	Supports
KRAS RS617643701
Cisplatin	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	3	accepted	EID872 In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was adde… (full text at CIViC) PMID 25081901 · Chung et al., 2014 · Open in CIViC	civic
KRAS Mutation23
Refametinib + SorafenibCombination	Hepatocellular Carcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID1642 Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was per… (full text at CIViC) PMID 25294897 · Lim et al., 2014 · Open in CIViC	civic
Salirasib	Lung Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1218 In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival … (full text at CIViC) PMID 21847063 · Riely et al., 2011 · Open in CIViC	civic
Abemaciclib	Lung Non-Small Cell CarcinomaCURATED_BROADER
KRAS G12A1
Erlotinib + GefitinibSubstitutes	Lung Adenocarcinoma	Predictive	B	Supports Resistance	3	accepted	EID251 KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) wer… (full text at CIViC) PMID 19794967 · Marchetti et al., 2009 · Open in CIViC	civic
KRAS G12D + TSC1 Loss-of-functionKRAS TSC11
Sirolimus	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID154 Following rapamycin treatment of mice with KrasG12D-induced lung adenocarcinomas, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, i… (full text at CIViC) PMID 19966866 · Liang et al., 2010 · Open in CIViC	civic
KRAS A146V1
Abemaciclib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID794 Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led… (full text at CIViC) PMID 24836576 · Van Allen et al., 2014 · Open in CIViC	civic
KRAS G12C4
Divarasib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID11652 A phase 1 clinical study conducted with Divarasib in a total of 137 patients, of which 60 patients had NSCLC with G12C mutation in the KRAS gene. Confirmed response was noted in 53.4% (95% CI; 39.9 to… (full text at CIViC) PMID 37611121 · Sacher et al., 2023 · Open in CIViC	civic
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID1142 83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size a… (full text at CIViC) PMID 26125448 · Jänne et al., 2015 · Open in CIViC	civic
Sotorasib
KRAS G12V3
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	1	accepted	EID1143 83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 accordin… (full text at CIViC) PMID 26125448 · Jänne et al., 2015 · Open in CIViC	civic
Palbociclib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	1	accepted	EID795 In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treat… (full text at CIViC) PMID 20609353 · Puyol et al., 2010 · Open in CIViC	civic
Cetuximab
KRAS G12/G132
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID35 In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201). PMID 15696205 · Pao et al., 2005 · Open in CIViC	civic
Bevacizumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Resistance	3	accepted	EID6295 This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
KRAS G13D6
Pictilisib	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	4	accepted	EID2041 This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID306 KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS. PMID 20978259 · De Roock et al., 2010 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B
KRAS Exon 2 Mutation2
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	A	Supports Resistance	5	accepted	EID993 KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone. 42% of… (full text at CIViC) PMID 18946061 · Karapetis et al., 2008 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID250 Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab. PMID 16618717 · Lièvre et al., 2006 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Gemcitabine	US FDA	Malignant Breast Neoplasm	in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.	approved	Aug 4, 2011	openfda
Gemcitabine	US FDA	Malignant Ovarian Neoplasm	in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.	approved	Aug 4, 2011	openfda
Irinotecan	CA Health Canada	—	Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02528800) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 12, 2024

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (1,652)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 798 recruiting · 366 active phase 3 · 7,948 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 301–350 of 1,652 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07293247	A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment	recruiting	Phase 2	164	Alliance for Clinical Trials in OncologyOTHER	1	Sep 2, 2026	clinicaltrials
NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	not yet recruiting	Phase 1	30	City of Hope Medical CenterOTHER	1	Sep 2, 2026	clinicaltrials
NCT07543172	CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer	not yet recruiting	Phase 2	29	Roswell Park Cancer InstituteOTHER	1	Sep 2, 2026	clinicaltrials
NCT07622186	A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)	recruiting	Phase 2	150	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY	1	Sep 2, 2026	clinicaltrials
NCT03600701	Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer	active not recruiting	Phase 2	53	National Cancer Institute (NCI)NIH	1	Sep 1, 2026	clinicaltrials
NCT04557956	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	active not recruiting	Phase 1 / Phase 2	16	National Cancer Institute (NCI)NIH	1	Sep 1, 2026	clinicaltrials
NCT04570423	A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy	recruiting	Phase 2	40	Spectrum Pharmaceuticals, IncINDUSTRY	1	Sep 1, 2026	clinicaltrials
NCT05054439	A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC	active not recruiting	Phase 2	45	Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY	1	Sep 1, 2026	clinicaltrials
NCT05355701	A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.	active not recruiting	Phase 1	103	PfizerINDUSTRY	3	Sep 1, 2026	clinicaltrials
NCT05627635	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	active not recruiting	Phase 1 / Phase 2	20	City of Hope Medical CenterOTHER	1	Sep 1, 2026	clinicaltrials
NCT05945823	Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors	active not recruiting	Phase 2	53	Taiho Oncology, Inc.INDUSTRY	4	Sep 1, 2026	clinicaltrials
NCT06294548	A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC	recruiting	Phase 1 / Phase 2	45	University of Alabama at BirminghamOTHER	1	Sep 1, 2026	clinicaltrials
NCT06523699	Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant	active not recruiting	Phase 1	30	Washington University School of MedicineOTHER	1	Sep 1, 2026	clinicaltrials
NCT06576037	Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin	recruiting	Phase 1	128	M.D. Anderson Cancer CenterOTHER	1	Sep 1, 2026	clinicaltrials
NCT06730750	A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors	active not recruiting	Phase 1 / Phase 2	360	Bristol-Myers SquibbINDUSTRY	3	Sep 1, 2026	clinicaltrials
NCT07564141	Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer(RAINFOL™-07)	recruiting	Phase 3	688	GenmabINDUSTRY	1	Sep 1, 2026	clinicaltrials
NCT03652428	Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)	active not recruiting	Phase 1 / Phase 2	24	University of Maryland, BaltimoreOTHER	1	Aug 31, 2026	clinicaltrials
NCT04538664	A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions(PAPILLON)	active not recruiting	Phase 3	308	Janssen Research & Development, LLCINDUSTRY	26	Aug 31, 2026	clinicaltrials
NCT04736173	Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer(ARC-10)	active not recruiting	Phase 2	169	Arcus Biosciences, Inc.INDUSTRY	10	Aug 31, 2026	clinicaltrials
NCT05896839	Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	recruiting	Phase 1 / Phase 2	16	National Cancer Institute (NCI)NIH	1	Aug 31, 2026	clinicaltrials
NCT07070440	DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)	recruiting	Phase 1 / Phase 2	180	Dizal PharmaceuticalsINDUSTRY	1	Aug 31, 2026	clinicaltrials
NCT07322341	SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer	recruiting	Phase 2	32	University of WashingtonOTHER	1	Aug 31, 2026	clinicaltrials
NCT07793942	A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)	not yet recruiting	Phase 2	480	Merck Sharp & Dohme LLCINDUSTRY	0	Aug 31, 2026	clinicaltrials
NCT07796126	Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status(HNSCC)	not yet recruiting	Phase 2	22	Barbara Ann Karmanos Cancer InstituteOTHER	1	Aug 31, 2026	clinicaltrials
NCT00070564	S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer	active not recruiting	Phase 3	3,294	SWOG Cancer Research NetworkNETWORK	3	Aug 28, 2026	clinicaltrials
NCT00602641	Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma	active not recruiting	Phase 3	306	National Cancer Institute (NCI)NIH	2	Aug 28, 2026	clinicaltrials
NCT01081262	Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer	active not recruiting	Phase 3	50	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	active not recruiting	Phase 1	50	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	active not recruiting	Phase 3	267	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT02270814	Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma(CACTUX)	active not recruiting	Phase 2	74	Washington University School of MedicineOTHER	1	Aug 28, 2026	clinicaltrials
NCT02339571	A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma	active not recruiting	Phase 2 / Phase 3	600	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT02839707	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 2 / Phase 3	444	National Cancer Institute (NCI)NIH	2	Aug 28, 2026	clinicaltrials
NCT04449874	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	active not recruiting	Phase 1	498	Genentech, Inc.INDUSTRY	17	Aug 28, 2026	clinicaltrials
NCT06132958	Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)(TroFuse-005)	active not recruiting	Phase 3	710	Merck Sharp & Dohme LLCINDUSTRY	31	Aug 28, 2026	clinicaltrials
NCT06682780	A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours	recruiting	Phase 1 / Phase 2	320	LaNova Medicines LimitedINDUSTRY	1	Aug 28, 2026	clinicaltrials
NCT06683755	Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)	recruiting	Phase 1 / Phase 2	30	M.D. Anderson Cancer CenterOTHER	1	Aug 28, 2026	clinicaltrials
NCT03811002	Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)	active not recruiting	Phase 3	544	National Cancer Institute (NCI)NIH	2	Aug 27, 2026	clinicaltrials
NCT05779423	Cryoablation+Ipilimumab+Nivolumab in Melanoma	recruiting	Phase 2	37	Massachusetts General HospitalOTHER	1	Aug 27, 2026	clinicaltrials
NCT06492070	Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers	recruiting	Phase 2	70	Emory UniversityOTHER	1	Aug 27, 2026	clinicaltrials
NCT06783647	A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]	recruiting	Phase 2	250	Nanjing Leads Biolabs Co.,LtdINDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT07474727	A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer	recruiting	Phase 2	180	Multitude Therapeutics Inc.INDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT07790510	HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer	recruiting	Phase 1 / Phase 2	180	Haisco Pharmaceutical Group Co., Ltd.INDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT00114101	Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant	active not recruiting	Phase 3	460	National Cancer Institute (NCI)NIH	1	Aug 26, 2026	clinicaltrials
NCT00334815	Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	active not recruiting	Phase 2	29	National Cancer Institute (NCI)NIH	1	Aug 26, 2026	clinicaltrials
NCT04025879	A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer	active not recruiting	Phase 3	461	Bristol-Myers SquibbINDUSTRY	22	Aug 26, 2026	clinicaltrials
NCT04329494	PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer	recruiting	Phase 1	49	City of Hope Medical CenterOTHER	1	Aug 26, 2026	clinicaltrials
NCT04656652	Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)	active not recruiting	Phase 3	605	Daiichi SankyoINDUSTRY	26	Aug 26, 2026	clinicaltrials
NCT05722015	A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)	active not recruiting	Phase 3	377	Merck Sharp & Dohme LLCINDUSTRY	16	Aug 26, 2026	clinicaltrials
NCT06212752	A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension	active not recruiting	Phase 3	39	Merck Sharp & Dohme LLCINDUSTRY	1	Aug 26, 2026	clinicaltrials
NCT06313970	First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients	active not recruiting	Phase 2	58	Fudan UniversityOTHER	1	Aug 26, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (26)

Drugs with predictive evidence (57)

Predictive evidence items (167)

Approvals mentioning the linked drugs (500)

Active trials (1,652)

Linked publications (113)